Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial.

ABSTRACT: AIMS:Exenatide is a glucagon-like peptide 1 (GLP-1) mimetic which induces weight loss predominantly, it is presumed, via decreased food intake. However, circulating GLP-1 is also a determinant of energy expenditure. We sought to quantify the effect of exenatide on energy expenditure (EE) and energy intake. MATERIALS AND METHODS:In this single-center, randomized double-blind placebo controlled trial, we randomized 80 healthy, non-diabetic volunteers with obesity (46 women, age: 34.4?±?8.7?y, body fat by DXA: 44.2?±?7.8%) to subcutaneous exenatide 10??g twice daily or placebo. Subjects were admitted to our clinical research unit for measurement of 24?h-EE in a whole-room indirect calorimeter and ad libitum food intake using an automated vending machine paradigm before and after randomization. Furthermore, energy expenditure and ad libitum food intake measures were repeated at 24-week after readmission for 7-day inpatient stay. Body weight was obtained weekly for up to 5?weeks and was recorded at each monthly follow up visit up to 24?weeks. RESULTS:Prior to randomization, participants over ate during the 3-day vending machine period in the whole study group (114.6?±?35.2%), expressed as percentage of weight maintaining energy needs (WMEN) with those who were eventually randomized to exenatide overeating more (121.6?±?37.7%) compared to placebo group (107.6?±?31.5%). In the exenatide group, ad libitum absolute energy intake decreased by 1016.1?±?724.5?kcal/day (95% CI: -1250.9 to -781.2) versus a 245.1?±?710.5?kcal/day (95% CI: -475.4 to -14.7) decrease in placebo (??=?-624.8?Kcal/day, p?

SUBMITTER: Basolo A 

PROVIDER: S-EPMC6062468 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature